摘要
目的探讨硫酸镁联合布地奈德混悬液雾化吸入对支气管哮喘急性发作患者疗效及对血清白介素12(IL-12)的影响。方法 100例支气管哮喘急性发作患者随机分为两组,对照组50例,治疗组50例;对照组在常规治疗基础加用口服强的松,治疗组在常规治疗的基础上加用硫酸镁联合布地奈德雾化吸入。观察两组呼吸功能的变化,并且测定患者血清IL-12。结果治疗组总疗效明显优于对照组(P<0.05);两组治疗后均可明显改善患者的呼吸功能,并且治疗组优于对照组(P<0.05);对照组和治疗组治疗前血清IL-12分别为(13.94±7.57)ng/L(,13.19±7.12)ng/L;治疗后两组分别为(18.35±8.74)ng/L(,22.19±6.92)ng/L;两组治疗后均可明显提高IL-12的表达(P<0.05),并且治疗组优于对照组(P<0.05)。结论硫酸镁联合布地奈德雾化吸入明显改善支气管哮喘急性发作患者的呼吸功能,IL-12的提高可能起重要作用。
Objectives To study the effectiveness of magnesium sulfate plus atomization inhaled budesonide on the interleukin-12 （IL-12） in the serum of patients with bronchial asthma in acute exacerbation. Methods One hundred patients with bronchial asthma in acute exacerbation were divided into two groups, the control group （n=50 cases） and the treatment group （n=50 cases） . They were all treated through the conventional treatment. The patients of the control group were additionally given oral prednisone, while the treatment group was additionally given magnesium sulfate plus atomization inhaled budesonide. The respiratory function and the IL-12 in the serum were detected before and after treatment. Results The total effect of the treatment group was prior to the control group （P〈0.05） . Compared with the control group, the respiratory function was significantly improved （P〈0.05） . The concentration of IL-12 was （13.94±7.57） ng/L in the control group and （13.19±7.12） ng/L in the treatment group before treatment, while （18.35±8.74） ng/L and （22.19±6.92） ng/L after treatment. They were significantly improved after treatment in both groups, especially in the treatment group （P〈0.05） . Conclusions Magnesium sulfate plus atomization inhaled budesonide could improve the respiratory function, IL-12 could be important.
出处
《中国医药指南》
2012年第20期412-413,共2页
Guide of China Medicine
